Home > Oncology > ASCO 2019 > Lung Cancer > Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC

Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC

Presented By
Dr Tina Cascone, University of Texas MD Anderson Cancer Centre, USA
Conference
ASCO 2019
Trial
NEOSTAR
Medical writer: Dave Levitan Neoadjuvant nivolumab plus ipilimumab offered a promising rate of major pathologic response (MPR) in patients with untreated, resectable non–small cell lung cancer (NSCLC), according to a phase II study (Abstract 8504). Nivolumab monotherapy also yielded some MPRs, although not at the prespecified threshold for efficacy. “More than 50% of patients with stage I to III resectable NSCLC will relapse if treated with surgery alone,” said Tina Cascone, MD, PhD, of The University of Texas MD Anderson Cancer Centre, during an Oral Abstract Session on June 1. Because tumour upregulation of PD-L1 is critical for the spread and survival of metastases in mouse models, anti–PD-1 therapy is being tested in the neoadjuvant setting to prime an anti-tumour response and eradicate micrometastases. The phase II NEOSTAR study included 44 patients with stage I to IIIA NSCLC who were considered surgical candidates; they were randomly selected t...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on